Amarin Corp Plc (AMRN)

[Jt0082]

This was a great point, and is consistent with JELIS.

JELIS actually found no benefit in CVD risk reduction in relation to baseline TG. However, subgroup analysis found that combination therapy with statin plus EPA reduced CVD risk by 53% (compared to statin monotherapy), in patients with baseline TG ≥150 mg/dL and HDL-C <40 mg/dL.

Interestingly, this CV benefit in JELIS was not attributed to TG lowering (difference in TG reduction was only 5% between groups).

I read this as positive for AMRN with regard to differentiating itself. To me it means scientists/physicians/FDA etc all need to be educated and there is obviously a lot more to V than purely just lowering trigs....